Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 8/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.72 |
| ▸ | HTR1A | P08908 | 5/20 | 0.72 |
| ▸ | KDM1A | O60341 | 4/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.72 |
| ▸ | DRD2 | P14416 | 4/20 | 0.72 |
| ▸ | TP53 | P04637 | 4/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.72 |
| ▸ | DRD1 | P21728 | 4/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.72 |
| ▸ | DRD3 | P35462 | 4/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.72 |
| ▸ | THPO | P40225 | 3/20 | 0.72 |
| ▸ | MTOR | P42345 | 3/20 | 0.72 |
| ▸ | PRNP | P04156 | 3/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prothipendyl SCHEMBL29393787 | 1.00 | CYP2D6 (0.72) | CYP2D6CYP1A2HTR1AKDM1ACYP2C19 | |
| Prothipendyl SCHEMBL5705613 | 0.99 | LMNA (0.72) | CYP2D6CYP1A2HTR1AKDM1ACYP2C19 | |
| Prothipendyl SCHEMBL1649843 | 0.99 | CYP2D6 (0.70) | CYP2D6CYP1A2HTR1AKDM1ACYP2C19 | |
| SCHEMBL26238573 | 0.95 | CYP2D6 (0.64) | CYP2D6CYP1A2HTR1AKDM1ACYP2C19 | |
| Promethazine SCHEMBL28860403 | 0.90 | KMT2A (0.77) | CYP2D6CYP1A2HTR1AKDM1ACYP2C19 | |
| SCHEMBL9833656 | 0.86 | CYP2D6 (0.66) | CYP2D6CYP1A2HTR1AKDM1ACYP2C19 | |
| SCHEMBL21214091 | 0.86 | CYP1A2 (0.61) | CYP2D6CYP1A2HTR1AKDM1ACYP2C19 | |
| SCHEMBL21196573 | 0.86 | CYP2D6 (0.52) | CYP2D6CYP1A2HTR1AKDM1ACYP2C19 | |
| Promazine SCHEMBL123419 | 0.84 | CYP2D6 (0.94) | CYP2D6CYP1A2HTR1AKDM1ACYP2C19 | |
| Promazine SCHEMBL9052694 | 0.84 | CYP2D6 (1.00) | CYP2D6CYP1A2HTR1AKDM1ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1811 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| US-12527754-B2 | Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions | TUFTS MEDICAL CENTER, INC. (US) | 2026-01-20 | — | — | US | claimed |
| EP-4618973-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | Sumitomo Pharma America, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250179064-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | AUSPEX PHARMACEUTICALS LLC | 2025-06-05 | — | — | US | claimed |
| WO-2025101418-A1 | TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS IN PATIENTS WITH PROMINENT ANHEDONIA USING IRDABISANT AS A MONOTHERAPY OR IN COMBINATION WITH AN ANTIPSYCHOTIC AGENT | ALTO NEUROSCIENCE, INC. (US) | 2025-05-15 | — | — | WO | claimed |
| US-20250144092-A1 | TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS IN PATIENTS WITH PROMINENT ANHEDONIA USING IRDABISANT AS A MONOTHERAPY OR IN COMBINATION WITH AN ANTIPSYCHOTIC AGENT | ALTO NEUROSCIENCE, INC. | 2025-05-08 | — | — | US | claimed |
| US-20240307220-A1 | Combination Therapy to Treat Temperature Sensitive Mutant Tumors | NATIONAL INSTITUTES OF HEALTH | 2024-09-19 | — | — | US | claimed |
| WO-2024107681-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| US-20240000810-A1 | USE OF CANNABINOIDS IN THE TREATMENT OF TOURETTE SYNDROME AND TIC DISORDERS | Orcosa Inc. (US) | 2024-01-04 | — | — | US | claimed |
| US-20030135202-A1 | Implantable osmotic pump | MICROSOLUTIONS, INC. | 2003-07-17 | — | — | US | claimed |
| US-20030125343-A1 | Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound | GAMBACORTI-PASSERINI CARLO (IT) | 2003-07-03 | — | — | US | claimed |
| CN-1414858-A | Combinations of receptor tyrosine kinase inhibitor with a1-acidic glycoprotein binding organic compound | NOVARTIS AG (CH) | 2003-04-30 | — | — | CN | claimed |
| US-20020183722-A1 | Implantable osmotic pump | MICROSOLUTIONS, INC., | 2002-12-05 | — | — | US | claimed |
| WO-2002085428-A2 | IMPLANTABLE OSMOTIC PUMP | MICROSOLUTIONS, INC. (US) | 2002-10-31 | — | — | WO | claimed |
| EP-1250140-A2 | COMBINATIONS OF A RECEPTOR TYROSINE KINASE INHIBITOR WITH ALPHA1-ACIDIC GLYCOPROTEIN BINDING COMPOUND | Novartis AG (CH) | 2002-10-23 | — | — | EP | claimed |
| WO-2001047507-A2 | COMBINATIONS OF RECEPTOR TYROSINE KINASE INHIBITOR WITH AN A1-ACIDIC GLYCOPROTEIN BINDING COMPOUND | NOVARTIS AG (CH) | 2001-07-05 | — | — | WO | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5314454-A | Method and apparatus of artifically stimulating cough reflex | JAEGER ROBERT J | 1994-05-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179064-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | ACAT2, CPT1A, SLC18A2 | CYP2D6 456/4885CYP1A2 327/4885HTR1A 747/4885 |
| US-12527754-B2 | Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions | GPR119, TPH1, LIPC | CYP2D6 284/4885CYP1A2 897/4885HTR1A 18/4885 |
| US-20030125343-A1 | Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound | PDGFRA, PDGFRB, TEK | CYP2D6 4240/4885CYP1A2 3988/4885HTR1A 2410/4885 |
| US-20250144092-A1 | TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS IN PATIENTS WITH PROMINENT ANHEDONIA USING IRDABISANT AS A MONOTHERAPY OR IN COMBINATION WITH AN ANTIPSYCHOTIC AGENT | GRIN2B, DRD2, SLC6A3 | CYP2D6 3387/4885CYP1A2 3914/4885HTR1A 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.